KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $7.1 million.

  • TherapeuticsMD's Cash & Equivalents rose 4097.48% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year increase of 4097.48%. This contributed to the annual value of $5.1 million for FY2024, which is 1691.7% up from last year.
  • TherapeuticsMD's Cash & Equivalents amounted to $7.1 million in Q3 2025, which was up 4097.48% from $6.1 million recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Cash & Equivalents peaked at $137.6 million during Q1 2021, and registered a low of $4.3 million during Q4 2023.
  • In the last 5 years, TherapeuticsMD's Cash & Equivalents had a median value of $13.7 million in 2023 and averaged $34.7 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 9122.61% in 2023, then surged by 4097.48% in 2025.
  • TherapeuticsMD's Cash & Equivalents (Quarter) stood at $64.9 million in 2021, then decreased by 24.02% to $49.3 million in 2022, then tumbled by 91.23% to $4.3 million in 2023, then grew by 16.92% to $5.1 million in 2024, then surged by 40.64% to $7.1 million in 2025.
  • Its Cash & Equivalents was $7.1 million in Q3 2025, compared to $6.1 million in Q2 2025 and $5.7 million in Q1 2025.